| Joshua Krieger, MD | |
|
1650 Cochrane Cir, Fort Carson, CO 80913-4613 | |
| (719) 526-7000 | |
| Not Available |
| Full Name | Joshua Krieger |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 8 Years |
| Location | 1650 Cochrane Cir, Fort Carson, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932569266 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uch-memorial Health System | Colorado springs, CO | Hospital |
| Lutheran Medical Center | Wheat ridge, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pulmonary Associates | 8729070305 | 14 |
News Archive
Department of Defense Secretary Robert Gates on Friday announced the creation of an independent panel to examine outpatient conditions at Walter Reed Army Medical Center and other military hospitals, the Los Angeles Times reports (Barnes, Los Angeles Times, 2/24).
President Obama on Friday named New York City Health Commissioner Thomas Frieden as the next CDC director, the New York Times reports. It has long been expected that Obama would select Frieden, an infectious disease specialist, according to the Times.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Cosmetics from the United States have been found to contain high levels of polyuoroalkyl substances (PFAS), associated with a range of harmful conditions.
Researchers have demonstrated for the first time that malfunction of a gene that had been associated with schizophrenia and depression does indeed cause symptoms of those disorders.
› Verified 4 days ago
| Entity Name | Usacs Of Colorado Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760415871 PECOS PAC ID: 4981507571 Enrollment ID: O20040130000439 |
News Archive
Department of Defense Secretary Robert Gates on Friday announced the creation of an independent panel to examine outpatient conditions at Walter Reed Army Medical Center and other military hospitals, the Los Angeles Times reports (Barnes, Los Angeles Times, 2/24).
President Obama on Friday named New York City Health Commissioner Thomas Frieden as the next CDC director, the New York Times reports. It has long been expected that Obama would select Frieden, an infectious disease specialist, according to the Times.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Cosmetics from the United States have been found to contain high levels of polyuoroalkyl substances (PFAS), associated with a range of harmful conditions.
Researchers have demonstrated for the first time that malfunction of a gene that had been associated with schizophrenia and depression does indeed cause symptoms of those disorders.
› Verified 4 days ago
| Entity Name | Emergency Service Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326097668 PECOS PAC ID: 1557255882 Enrollment ID: O20040209001037 |
News Archive
Department of Defense Secretary Robert Gates on Friday announced the creation of an independent panel to examine outpatient conditions at Walter Reed Army Medical Center and other military hospitals, the Los Angeles Times reports (Barnes, Los Angeles Times, 2/24).
President Obama on Friday named New York City Health Commissioner Thomas Frieden as the next CDC director, the New York Times reports. It has long been expected that Obama would select Frieden, an infectious disease specialist, according to the Times.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Cosmetics from the United States have been found to contain high levels of polyuoroalkyl substances (PFAS), associated with a range of harmful conditions.
Researchers have demonstrated for the first time that malfunction of a gene that had been associated with schizophrenia and depression does indeed cause symptoms of those disorders.
› Verified 4 days ago
| Entity Name | Pulmonary Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760409676 PECOS PAC ID: 8729070305 Enrollment ID: O20040401001696 |
News Archive
Department of Defense Secretary Robert Gates on Friday announced the creation of an independent panel to examine outpatient conditions at Walter Reed Army Medical Center and other military hospitals, the Los Angeles Times reports (Barnes, Los Angeles Times, 2/24).
President Obama on Friday named New York City Health Commissioner Thomas Frieden as the next CDC director, the New York Times reports. It has long been expected that Obama would select Frieden, an infectious disease specialist, according to the Times.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Cosmetics from the United States have been found to contain high levels of polyuoroalkyl substances (PFAS), associated with a range of harmful conditions.
Researchers have demonstrated for the first time that malfunction of a gene that had been associated with schizophrenia and depression does indeed cause symptoms of those disorders.
› Verified 4 days ago
| Entity Name | Usacs Observation Medicine Services Of Colorado Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518491232 PECOS PAC ID: 9133498074 Enrollment ID: O20170707002144 |
News Archive
Department of Defense Secretary Robert Gates on Friday announced the creation of an independent panel to examine outpatient conditions at Walter Reed Army Medical Center and other military hospitals, the Los Angeles Times reports (Barnes, Los Angeles Times, 2/24).
President Obama on Friday named New York City Health Commissioner Thomas Frieden as the next CDC director, the New York Times reports. It has long been expected that Obama would select Frieden, an infectious disease specialist, according to the Times.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Cosmetics from the United States have been found to contain high levels of polyuoroalkyl substances (PFAS), associated with a range of harmful conditions.
Researchers have demonstrated for the first time that malfunction of a gene that had been associated with schizophrenia and depression does indeed cause symptoms of those disorders.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Krieger, MD 1650 Cochrane Cir, Department Of Emergency Medicine, Fort Carson, CO 80913-4613 Ph: (719) 526-7000 | Joshua Krieger, MD 1650 Cochrane Cir, Fort Carson, CO 80913-4613 Ph: (719) 526-7000 |
News Archive
Department of Defense Secretary Robert Gates on Friday announced the creation of an independent panel to examine outpatient conditions at Walter Reed Army Medical Center and other military hospitals, the Los Angeles Times reports (Barnes, Los Angeles Times, 2/24).
President Obama on Friday named New York City Health Commissioner Thomas Frieden as the next CDC director, the New York Times reports. It has long been expected that Obama would select Frieden, an infectious disease specialist, according to the Times.
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Cosmetics from the United States have been found to contain high levels of polyuoroalkyl substances (PFAS), associated with a range of harmful conditions.
Researchers have demonstrated for the first time that malfunction of a gene that had been associated with schizophrenia and depression does indeed cause symptoms of those disorders.
› Verified 4 days ago
Matthew Nilan, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1650 Cochrane Cir, Fort Carson, CO 80913 Phone: 719-728-0869 | |
Sam Blair, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1650 Cochrane Cir, Fort Carson, CO 80913 Phone: 719-526-7000 | |
Dr. William L Black, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1650 Cochrane Cir, Fort Carson, CO 80913 Phone: 719-526-7844 Fax: 719-526-7894 | |
Neil Patrick Larson, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1650 Cochrane Cir Unit Meddac, Fort Carson, CO 80913 Phone: 719-526-7000 | |
Diane Marie Greilich, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1650 Cochrane Circle, Credentials Office, Fort Carson, CO 80913 Phone: 719-526-2092 Fax: 907-452-3524 | |
Taylor Rebecca Reffett, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1650 Cochrane Cir Unit Meddac, Fort Carson, CO 80913 Phone: 719-526-7000 | |
Todd J Mcarthur, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1650 Cochrane Cir, Evans Army Community Hospital, Fort Carson, CO 80913 Phone: 719-526-7000 |